Corcept Therapeutics Reports Statistically Significant Overall Survival Benefit for Lifyorli in Platinum-Resistant Ovarian Cancer at ASCO 2026 Corcept Therapeutics Incorporated, a commercial-stage biopharmaceutical company focused on discovering and developing therapies…
Veracyte’s Prosigna Test Shows Practice-Changing Results in Early Breast Cancer at ASCO 2026 OPTIMA Trial Veracyte, Inc., a leading cancer diagnostics company, has announced highly significant results from the independent…
Virion Therapeutics Reports Durable Functional Cure Signals in Chronic Hepatitis B with Single-Dose VRON-0200 at EASL 2026 Virion Therapeutics, LLC, a clinical-stage biotechnology company focused on developing next-generation T cell–based…
Beren Therapeutics to Present Comprehensive Adrabetadex Data at 2026 NPC Research Conference, Highlighting Early Treatment Benefits and Mechanistic Insights Beren Therapeutics P.B.C., the parent company of Mandos LLC and a…
Bristol Myers Squibb’s Mezigdomide Combo Shows Strong Phase 3 Success in Relapsed Multiple Myeloma at ASCO 2026 Bristol Myers Squibb has announced encouraging late-breaking results from the Phase 3 SUCCESSOR-2…
PanTher Therapeutics Advances PTM-101 with Phase 1b Dose Escalation Completion in Pancreatic Cancer and Appoints Oncology Veteran Tim Clackson to Board PanTher Therapeutics, a clinical-stage biotechnology company developing implant-based localized…
Canopy Growth Relaunches Tweed Brand in Germany and Expands Medical Cannabis Portfolio Following MTL Acquisition Canopy Growth Corporation has announced a major strategic milestone in its international expansion strategy with…
Meiji Seika Pharma Invests in Global Health Security Fund to Advance Pandemic Preparedness and Infectious Disease Innovation Meiji Seika Pharma Co., Ltd., one of Japan’s leading pharmaceutical companies with a…
Merck’s Investigational KRAS Inhibitor Calderasib Receives FDA Breakthrough Therapy Designation for First-Line KRAS G12C-Mutated Lung Cancer Merck, known as MSD outside the United States and Canada, has announced a significant…
BeOne Medicines Showcases Long-Term BRUKINSA Success and Next-Generation CLL Treatment Advances at ASCO 2026 BeOne Medicines Ltd., a global oncology company dedicated to developing innovative cancer therapies, is presenting extensive…
CorWave Achieves ISO 13485 Certification, Advancing Commercialization Plans for Innovative Heart Failure Devices CorWave, a clinical-stage medical technology company focused on developing next-generation cardiac assist devices, has announced a significant…
IMFINZI® (durvalumab) Becomes First Approved Immunotherapy Combination in the U.S. for Patients with BCG-Naïve High-Risk Non-Muscle-Invasive Bladder Cancer AstraZeneca has secured a significant new regulatory milestone for its immunotherapy IMFINZI…